650629-19-9 Usage
Uses
Used in Pharmaceutical Research:
Uridine, 3'-deoxy-5-fluoro-, 5'-(2-nitrobenzenepropanoate) is utilized as a research compound for the development of novel therapeutic agents. Its unique chemical structure may provide insights into the design of new drugs targeting specific biological pathways or mechanisms, particularly in the context of RNA-related diseases or conditions.
Used in Nucleic Acid Studies:
In the field of molecular biology, this modified nucleoside is employed as a tool for studying the structure, function, and interactions of nucleic acids. Its incorporation into RNA molecules can help researchers understand the effects of structural modifications on RNA stability, folding, and recognition by proteins or other molecules.
Used in Drug Development:
Uridine, 3'-deoxy-5-fluoro-, 5'-(2-nitrobenzenepropanoate) is used as a potential precursor or intermediate in the synthesis of new pharmaceuticals. Its modified structure may confer specific biological activities or improve the pharmacokinetic properties of drug candidates, such as enhancing solubility, stability, or targeting efficiency.
Used in Chemical Synthesis:
Uridine, 3'-deoxy-5-fluoro-, 5'-(2-nitrobenzenepropanoate) may also find application in the synthesis of other complex organic molecules, including those with potential biological or medicinal relevance. Its unique functional groups can serve as starting points or intermediates in the assembly of more intricate chemical structures.
Check Digit Verification of cas no
The CAS Registry Mumber 650629-19-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 6,5,0,6,2 and 9 respectively; the second part has 2 digits, 1 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 650629-19:
(8*6)+(7*5)+(6*0)+(5*6)+(4*2)+(3*9)+(2*1)+(1*9)=159
159 % 10 = 9
So 650629-19-9 is a valid CAS Registry Number.
650629-19-9Relevant academic research and scientific papers
5′-(2-Nitrophenylalkanoyl)-2′-deoxy-5-fluorouridines as potential prodrugs of FUDR for reductive activation
Liu, Bin,Hu, Longqin
, p. 3889 - 3899 (2007/10/03)
Four 5′-(2-nitrophenylalkanoyl)-2′-deoxy-5-fluorouridines (1a-d) were designed and synthesized as potential prodrugs of FUDR for reductive activation. Two methyl groups were introduced α to the ester carbonyl to increase both the rate of cyclization activation and the stability of the conjugates towards serum esterases. Chemical reduction of the nitro group into an amino leads to cyclization and release of the active FUDR. Kinetic analysis of the cyclization activation process indicates that the two methyl groups α to the ester carbonyl restrict the rotational freedom of ground state molecule and promote the cyclization reaction. However, the two methyl groups also were found to render the conjugates as poor substrates of E. coli B nitroreductase. Conjugate 1c, without the two methyl groups, was reduced by E. coli B nitroreductase (t1/2=8 h) to give two products, a N-hydroxyl lactam and the drug FUDR, suggesting that the enzymatic reduction and subsequent cyclization activation proceeded through the hydroxylamine intermediate. These results indicate that cyclization activation will occur once the nitro group is reduced either to an amino or to a hydroxylamino group. The fact that the amino intermediates cyclized easily to release the incorporated drug FUDR suggests the feasibility of using peptide-linked acyl 2-aminophenylalkanoic acid esters as potential prodrugs for proteolytic activation.
